Arcus Bio's EDGE-Gastric Ph2 shows median OS 26.7 months; ORR 59%

Arcus Biosciences, Inc.

Median OS 26.7 months (90% CI: 18.4, NE) for all patients (n=41); PD-L1 high subgroup NE.
Confirmed ORR 59% (24/41) per RECIST v1.1; 62% in PD-L1 positive and 69% in PD-L1 high subgroups.
Median PFS 12.9 months overall; 24-month OS rate 50.2% and PFS rate 25.9%.
Median follow-up 26.4 months; median time on domvanalimab+zimberelimab+chemo was 49 weeks.
No unexpected safety signals; immune-mediated TEAEs in 22% of patients, infusions reactions in 7%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.